ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer
Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting
Updated Data from Carboplatin Dose-Escalation Cohort Demonstrate Increased Response Rate and Durable Benefit with Longer-Term Follow Up
Conference Call Scheduled for
“Building upon the encouraging data generated with mirvetuximab
monotherapy, we have looked to expand our addressable patient population
through combination regimens with both currently approved and
experimental agents in ovarian cancer. In dose escalation, we have
demonstrated that full dose mirvetuximab can be combined safely with
full doses of Avastin, carboplatin, or Keytruda, with encouraging
preliminary clinical activity,” said
Berkenblit continued, “In addition, we plan to present initial data from the Keytruda expansion cohort later this year, building upon the dose escalation data recently presented at SGO. The totality of these data from FORWARD II will guide the next stages of development of mirvetuximab and support a path to registration for combination regimens.”
DATA FROM FORWARD II EXPANSION COHORT WITH AVASTIN
Mirvetuximab
soravtansine in combination with Avastin in patients with
platinum-resistant ovarian cancer has demonstrated anti-tumor activity
with durable responses and a favorable tolerability profile,
particularly among the subset of patients who have received up to three
prior lines of therapy and have medium or high levels of FRα expression.
This is the population being studied in the FORWARD I Phase 3
registration trial.
Key findings in 59 patients with platinum-resistant ovarian cancer include:
- In the subset of 23 patients evaluable for response with medium or high FRα expression levels who have received up to three prior lines of therapy, the confirmed overall response rate (ORR) was 48 percent (95% CI 27,69), with a median progression-free survival (PFS) of 9.9 months (95% CI 4.6,14.5) and a median duration of response (DOR) of 10.6 months (95% CI 3.3,12.0).
- For the 54 patients evaluable for response, the confirmed ORR was 43 percent (95% CI 29,57), with a median PFS of 7.8 months (95% CI 5.6,10.2); patients in this cohort had received a median of 3 prior lines of systemic therapy, with 58 percent of patients having received prior bevacizumab.
- The combination continues to display a safety profile in-line with the known profiles of each agent, with no new safety signals identified.
“The mirvetuximab and Avastin combination has demonstrated very
encouraging initial clinical activity in ovarian cancer patients and a
consistently favorable safety profile,” stated
ASCO PRESENTATION DETAILS
Title: Mirvetuximab
soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug
conjugate (ADC), in combination with bevacizumab in patients (pts) with
platinum-resistant ovarian cancer: maturing safety and activity profile
from the FORWARD II Phase 1b study
Presenter: David M.
O’Malley, MD,
Day/Time:
Location: Hall A
Abstract:
5549
Additional information, can be found at www.asco.org.
UPDATED DATA FROM FORWARD II DOSE-ESCALATION COHORT WITH CARBOPLATIN
Initial
findings from a dose escalation cohort of mirvetuximab in combination
with carboplatin were presented at
- In the subset of 10 patients with medium or high FRα expression levels, the confirmed ORR was 80 percent (95% CI 44,98), with a median PFS of 15 months (95% CI 9.9,-), and with median DOR not reached.
- For all 17 evaluable patients, the confirmed ORR was 71 percent (95% CI 44,90), with a median PFS of 15 months (95% CI 9.9, -), and with median DOR not reached; 50 percent of patients in this cohort had received 3 or more prior lines of systemic therapy.
- The combination continues to display a favorable safety profile in-line with the known profiles of each agent, with no new safety signals identified.
Based on the findings from the carboplatin and Avastin cohorts, ImmunoGen recently initiated an additional cohort assessing a triplet combination of mirvetuximab plus carboplatin and Avastin in patients with recurrent platinum-sensitive ovarian cancer as part of the FORWARD II trial.
DATA FROM FORWARD II DOSE-ESCALATION COHORT WITH KEYTRUDA
Additionally,
ImmunoGen recently announced
encouraging activity and favorable tolerability data from the FORWARD II
cohort assessing mirvetuximab in combination with Merck’s anti-PD-1
therapy Keytruda® (pembrolizumab) in patients with
platinum-resistant ovarian cancer at the
CONFERENCE CALL INFORMATION
ImmunoGen will host a conference
call on
ABOUT FORWARD II
FORWARD II is a Phase 1b/2 study of
mirvetuximab in combination with Avastin (bevacizumab), carboplatin or
Keytruda (pembrolizumab) in patients with FRα-positive
platinum-resistant ovarian cancer, primary peritoneal, or fallopian tube
tumors, as well as a triplet combination of mirvetuximab plus
carboplatin and Avastin in patients with platinum-sensitive ovarian
cancer.
ABOUT MIRVETUXIMAB SORAVTANSINE
Mirvetuximab soravtansine
(IMGN853) is the first folate receptor alpha (FRα)-targeting ADC. It
uses a humanized FRα-binding antibody to target the ADC specifically to
FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill
the targeted cancer cells.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation
of antibody-drug conjugates (ADCs) to improve outcomes for cancer
patients. By generating targeted therapies with enhanced anti-tumor
activity and favorable tolerability profiles, we aim to disrupt the
progression of cancer and offer our patients more good days. We call
this our commitment to “target a better now.” Our lead product
candidate, mirvetuximab soravtansine, is in Phase 3 study for folate
receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in
Phase 1b/2 testing in combination regimens. Our novel IGN candidates for
hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
Keytruda® and Avastin® are registered trademarks of their respective owners.
This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's ability to expand the addressable patient population for mirvetuximab soravtansine and the regulatory and commercial potential of mirvetuximab combinations in earlier lines of therapy. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results, and the potential that earlier clinical studies may not be predictive of future results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and other reports filed with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180516006456/en/
Source:
ImmunoGen, Inc.
INVESTOR RELATIONS CONTACT
Sarah Kiely,
781-895-0600
sarah.kiely@immunogen.com
or
MEDIA
CONTACT
Courtney O’Konek, 781-895-0600
courtney.okonek@immunogen.com
or
FTI
Consulting
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com